These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Reported results||2011-004481-15||An open-label phase II trial of erlotinib and bevacizumab in patients with advanced non-small cell lung cancer and activating EGFR mutations||2018-10-31||due-trials|
|Listed as ongoing, but also has a completion date and reported results||2012-001896-35||A randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer who failed first line platinum based doublet chemotherapy stratified by Ve...||2015-12-31||bad-data|
|Ongoing||2013-002609-78||A randomised open-label phase II trial of consolidation ipilimumab in limited-stage SCLC after chemo-radiotherapy||not-yet-due|
|Listed as ongoing, but also has a completion date||2013-003156-21||A randomised, open-label phase III trial evaluating the addition of denosumab to standard first-line anticancer treatment in advanced NSCLC||2020-02-29||bad-data|
|Listed as ongoing, but also has a completion date||2014-005097-11||A feasibility trial evaluating anti-PD1 nivolumab consolidation after standard first-line chemotherapy and radiotherapy in locally advanced stage IIIA/B NSCLC||2020-03-31||bad-data|
|Reported results||2014-005098-35||Afatinib in pretreated patients with advanced NSCLC harbouring HER2 exon 20 mutations||2017-09-15||due-trials|
|Ongoing||2016-002029-12||A randomised phase II trial of osimertinib and bevacizumab versus osimertinib alone as second-line treatment in stage IIIb-IVb NSCLC with confirmed EGFRm and T790M||not-yet-due|
|Ongoing||2016-002062-31||A multicentre randomised phase III trial comparing pembrolizumab versus standard chemotherapy for advanced pre-treated malignant pleural mesothelioma||not-yet-due|
|Ongoing||2017-002063-17||A single arm phase II trial evaluating the activity of alectinib for the treatment of pretreated RET-rearranged advanced NSCLC||not-yet-due|
|Ongoing||2018-002180-25||A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant p...||not-yet-due|
|Ongoing||2018-003011-22||A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy and stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the primary ...||not-yet-due|
|Ongoing||2019-001687-30||A randomised non-comparative open label phase II trial of atezolizumab plus bevacizumab, with carboplatin-paclitaxel or pemetrexed, in EGFR mutant non-small cell lung carcinoma with acquired resistanc...||not-yet-due|